Trial Profile
A phase II trial of 506U78 (IND 52611) [nelarabine] in patients with relapsed or refractory non T-cell acute lymphoblastic leukemia (ALL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 25 Sep 2005 New trial record.